论文信息 - Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. - 字舞流文

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.

P. Hari | N. Shah | M. Hamadani | T. Fenske | J. Zurko | E. Aschenbrenner | Bryon D. Johnson

[1] Michael R. Green,et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma , 2021, Blood.

[2] Bryon D Johnson,et al. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma , 2020, Bone Marrow Transplantation.

[3] Matthew J. Frigault,et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4] Michael R. Green,et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. , 2020, Blood advances.

[5] P. Hari,et al. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. , 2020, Blood advances.

[6] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.